Pluslife Biotech – Mini Dock POC Molecular System

The Pluslife Mini Dock System is a Next-Generation POC molecular diagnostic tool that can be used in different application scenarios, which aims to help the decentralization of MDx in diagnosing facilities.

Complete POC Molecular Testing Solution (Isothermal Amplification Chip Method)

Analyzers, Mini Dock and 8-Channel
16 Tests,
- Pandemic Control - SARS-CoV-2, Monkeypox
- Respiratory Health - SARS-CoV-2/Flu A/Flu B, RSV/Flu A/Flu B, Strep A, M.P
- Sexual Health - STD (NG/UU), STD (CT/NG/UU), HPV 16/18/45, HPV 6/11, Strep B (GBS)
- Animal Health - Feline (FHV-1/C.felis/M.felis), Feline (FHV-1/C.felis/M.felis/Bb), Canine (CDV/CPIV/CAV-2/Bb), ASFV

Features:

Performance: 98.91% Sensitivity, 100% Speciﬁcity, LoD 400 Copies/mL
Compact,
- Palmed-sized Mink Dock (~210g), weight less than iPhone 14 (~240g)
- 8-Channel Analyzer, benchtop and stackable design
Accurate, equivalent to qPCR tests
Fast, 3-step process (sampling → mixing → run test), results in 15~30 mins
Powerful, one test up to 6 pathogens
Competitive Cost, reusable analyzers and room temperature storage test cards

Find us at MEDICA 2022 Booth No.1 1H39-7 or visit https://www.pluslife.com/ for more detail.

Website: https://www.pluslife.com/

03.11.2022

The Global Alliance for Diagnostics Sets Next-Generation POC Molecular Testing Collaboration

The coronavirus pandemic is a huge challenge for global public health and welfare. Decentralized, affordable POC MDx platforms would allow more effective control of SARS-CoV-2 and other infections.

News • "COMPASS" method

Using nanoparticles for more sensitive rapid tests

A newly developed rapid test needs only a few seconds to reliably detect pathogens such as SARS-CoV-2. It is based on specially designed magnetic nanoparticles.

News • Deep mutational scanning for SARS-CoV-2

Preparing rapid tests for future coronavirus variants

How can rapid antigen tests be adjusted to reliably detect future variants of SARS-CoV-2? A research team funded by the National Institutes of Health is currently working on finding an answer.